142 related articles for article (PubMed ID: 29482577)
1. Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.
Zheng Z; Fan S; Zheng J; Huang W; Gasparetto C; Chao NJ; Hu J; Kang Y
J Hematol Oncol; 2018 Feb; 11(1):29. PubMed ID: 29482577
[TBL] [Abstract][Full Text] [Related]
2. The STAT3 inhibitor stattic overcome bortezomib-resistance in multiple myeloma via decreasing PSMB6.
Yuan C; Yuan M; Li W; Cheng H; Luo J; Zhang Q; Shi M; Niu M; Yang J; Sun Z; Yan Z; Xu K; Li Z; Yao Y
Exp Cell Res; 2023 Aug; 429(1):113634. PubMed ID: 37207970
[TBL] [Abstract][Full Text] [Related]
3. Tigecycline Opposes Bortezomib Effect on Myeloma Cells Decreasing Mitochondrial Reactive Oxygen Species Production.
Ramos-Acosta C; Huerta-Pantoja L; Salazar-Hidalgo ME; Mayol E; Jiménez-Vega S; García-Peña P; Jordi-Cruz J; Baquero C; Porras A; Íñigo-Rodríguez B; Benavente CM; López-Pastor AR; Gómez-Delgado I; Urcelay E; Candel FJ; Anguita E
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732105
[TBL] [Abstract][Full Text] [Related]
4. A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax.
Downey-Kopyscinski SL; Srinivasa S; Kisselev AF
Sci Rep; 2022 Jul; 12(1):12788. PubMed ID: 35896610
[TBL] [Abstract][Full Text] [Related]
5. 5-Aza-2'-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential.
Łuczkowska K; Kulig P; Rusińska K; Baumert B; Machaliński B
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069103
[TBL] [Abstract][Full Text] [Related]
6. The NEDD4-1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma.
Huang X; Gu H; Zhang E; Chen Q; Cao W; Yan H; Chen J; Yang L; Lv N; He J; Yi Q; Cai Z
Int J Cancer; 2020 Apr; 146(7):1963-1978. PubMed ID: 31390487
[TBL] [Abstract][Full Text] [Related]
7. NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma.
Xia J; He Y; Meng B; Chen S; Zhang J; Wu X; Zhu Y; Shen Y; Feng X; Guan Y; Kuang C; Guo J; Lei Q; Wu Y; An G; Li G; Qiu L; Zhan F; Zhou W
Mol Oncol; 2020 Apr; 14(4):763-778. PubMed ID: 31955515
[TBL] [Abstract][Full Text] [Related]
8. Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines.
Zeissig MN; Hewett DR; Mrozik KM; Panagopoulos V; Wallington-Gates CT; Spencer A; Dold SM; Engelhardt M; Vandyke K; Zannettino ACW
Leuk Res; 2024 Apr; 139():107469. PubMed ID: 38479337
[TBL] [Abstract][Full Text] [Related]
9. Targeting PARP14 with lomitapide suppresses drug resistance through the activation of DRP1-induced mitophagy in multiple myeloma.
Zhang H; Wang H; Hu Y; Gao Y; Chen J; Meng Y; Qiu Y; Hu R; Liao P; Li M; He Y; Liang Z; Xie X; Li Y
Cancer Lett; 2024 Apr; 588():216802. PubMed ID: 38467180
[TBL] [Abstract][Full Text] [Related]
10. Lactate Decreases Bortezomib Sensitivity and Predicts Poor Clinical Outcomes of Multiple Myeloma.
Ma NY; Li Q; Li XL; Zeng YJ; Huang DZ; Duan YS; Xia J; Liu BD; Rao LY; Rao J; Zhang X
Curr Med Sci; 2023 Aug; 43(4):679-688. PubMed ID: 37326888
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Sphingosine Kinase 2 Results in PARK2-Mediated Mitophagy and Induces Apoptosis in Multiple Myeloma.
Wu J; Fan S; Feinberg D; Wang X; Jabbar S; Kang Y
Curr Oncol; 2023 Mar; 30(3):3047-3063. PubMed ID: 36975444
[TBL] [Abstract][Full Text] [Related]
12. Methylcrotonyl-CoA carboxylase subunit 1 (MCCA) regulates multidrug resistance in multiple myeloma.
Feng Y; Huang J; Wang F; Lin Z; Luo H; Li Q; Wang X; Liu X; Zhai X; Gao Q; Li L; Zhang Y; Wen J; Zhang L; Niu T; Zheng Y
Life Sci; 2023 Nov; 333():122157. PubMed ID: 37805164
[TBL] [Abstract][Full Text] [Related]
13. TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy.
Chen J; Cao W; Huang X; Chen Q; Ye S; Qu J; Liu Y; Guo X; Yao S; Zhang E; He J; Li A; Yang L; Cai Z
Blood Adv; 2023 Oct; 7(19):5752-5770. PubMed ID: 37083684
[TBL] [Abstract][Full Text] [Related]
14. S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma.
Wang Y; Muylaert C; Wyns A; Vlummens P; De Veirman K; Vanderkerken K; Zaal E; Berkers C; Moreaux J; De Bruyne E; Menu E
Haematologica; 2024 Jan; 109(1):256-271. PubMed ID: 37470139
[TBL] [Abstract][Full Text] [Related]
15. MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.
Pak C; Callander NS; Young EW; Titz B; Kim K; Saha S; Chng K; Asimakopoulos F; Beebe DJ; Miyamoto S
Integr Biol (Camb); 2015 Jun; 7(6):643-54. PubMed ID: 25998180
[TBL] [Abstract][Full Text] [Related]
16. Experimental study on thioredoxin redox inhibitor 1-methylpropyl 2-imidazolyl disulfide promoting apoptosis of multiple myeloma cells in vitro and in vivo.
Lin QD; Liu LN; Liu XY; Yan Y; Fang BJ; Zhang YL; Zhou J; Li YF; Zuo WL; Song YP
Eur Rev Med Pharmacol Sci; 2022 Feb; 26(4):1283-1292. PubMed ID: 35253185
[TBL] [Abstract][Full Text] [Related]
17. The EGFL7-ITGB3-KLF2 axis enhances survival of multiple myeloma in preclinical models.
Salama Y; Heida AH; Yokoyama K; Takahashi S; Hattori K; Heissig B
Blood Adv; 2020 Mar; 4(6):1021-1037. PubMed ID: 32191808
[TBL] [Abstract][Full Text] [Related]
18. Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma.
Zhu Y; Jian X; Chen S; An G; Jiang D; Yang Q; Zhang J; Hu J; Qiu Y; Feng X; Guo J; Chen X; Li Z; Zhou R; Hu C; He N; Shi F; Huang S; Liu H; Li X; Xie L; Zhu Y; Zhao L; Jiang Y; Li J; Wang J; Qiu L; Chen X; Jia W; He Y; Zhou W
Cell Metab; 2024 Jan; 36(1):159-175.e8. PubMed ID: 38113887
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D and K Supplementation Is Associated with Changes in the Methylation Profile of U266-Multiple Myeloma Cells, Influencing the Proliferative Potential and Resistance to Bortezomib.
Łuczkowska K; Kulig P; Baumert B; Machaliński B
Nutrients; 2023 Dec; 16(1):. PubMed ID: 38201971
[TBL] [Abstract][Full Text] [Related]
20. An orthotopic syngeneic mouse model of bortezomib-resistant multiple myeloma.
Li M; Bennett MK; Toubia J; Pope VS; Tea MN; Tamang S; Samuel MS; Anderson PH; Gliddon BL; Powell JA; Pitson SM
Br J Haematol; 2024 Feb; 204(2):566-570. PubMed ID: 38053270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
